Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1936)	4/7/2003 12:52:19 PM
From: tuck	Read Replies (1) \| Respond to of 2243

>>Allan suggested it on the basis of slavery<< ? Looking at a chart for a few minutes is slavery? Would you like a little FA with your TA? I submit I might have slaved a little harder over that. Message 18782965 Message 18785878 Here I wondered aloud what they might add that wasn't in the abstract. This morning's press release gives me the answer: the circulating tumor data. OK, it just got priced in. Message 18806325 Or did it? I ask again, since you're an immunologist and I'm not . . . >> your take on PI data? No response rates accept circulating tumors, which come back as the immune response wears off. Can treatment be continued effectively? Does this also imply it's not doing anything to the primary tumors? Might help in combo with something that does?<< Cheers, Tuck